The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors
Open accessAbstract
Background and objectives: Immune checkpoint inhibitor use in oncology is increasing rapidly. We sought to determine the frequency, severity, cause, and predictors of AKI in a real-world population receiving checkpoint inhibitors. Design, setting, participants, & measurements: We included all patients who received checkpoint inhibitor therapy from May 2011 to December 2016 at Massachusetts General Hospital. Baseline serum creatinine, averaged 6 months before checkpoint inhibitor start date, was compared with all subsequent creatinine values within 12 months of starting therapy. AKI was defined by Kidney Disease: Improving Global Outcomes criteria for fold changes in creatinine from baseline. Sustained AKI events lasted at least 3 days and was our primary outcome. The cause of sustained AKI was determined by chart review. Cumulative incidence and subdistribution hazard models were used to assess the relationship between baseline demographics, comorbidities, and medications, and sustained AKI and potential checkpoint inhibitor–related AKI. Results: We included 1016 patients in the analysis. Average age was 63 (SD 13) years, 61% were men, and 91% were white. Mean baseline creatinine was 0.9 mg/dl (SD 0.4 mg/dl), and 169 (17%) had CKD (eGFR<60 ml/min per 1.73 m 2) at baseline. A total of 169 patients (17%) experienced AKI, defined by an increase in creatinine at least 1.5 times the baseline within 12 months; 82 patients (8%) experienced sustained AKI and 30 patients (3%) had potential checkpoint inhibitor–related AKI. The first episode of sustained AKI occurred, on average, 106 days (SD 85) after checkpoint inhibitor initiation. Sixteen (2%) patients experienced stage 3 sustained AKI and four patients required dialysis. Proton pump inhibitor use at baseline was associated with sustained AKI. Conclusions: AKI is common in patients receiving checkpoint inhibitor therapy. The causes of sustained AKI in this population are heterogenous and merit thorough evaluation. The role of PPI and other nephritis-inducing drugs in the development of sustained AKI needs to be better defined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · cited 1×
“Fine and Gray subdistribution hazard function was used to estimate the risk of sustained AKI in patients with advanced malignancies given their baseline characteristics (25,26).”
MethodPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock, D. G., Levin, A., & the Acute Kidney Injury Network (2007) · Critical Care · doi:10.1186/cc5713 · Cited by 7,048
Bellomo, R., Ronco, C., Kellum, J. A., Mehta, R. L., Palevsky, P., & workgroup, T. A. (2004) · Critical Care · doi:10.1186/cc2872 · Cited by 6,781
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.1 · Cited by 4,326
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Introduction to the Analysis of Survival Data in the Presence of Competing Risks
Austin, P. C., Lee, D. S., & Fine, J. P. (2016) · Circulation · doi:10.1161/circulationaha.115.017719 · Cited by 2,653
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · cited 3×
“73 m(2) 406 (40) 369 (40) 37 (45) 12 (46) Immune checkpoint inhibitor class PD1 agents 701 (69) 650 (69) 51 (62) 16 (53) CTLA4 agents 249 (24) 223 (24) 26 (32) 12 (40) PDL1 agents 37 (4) 34 (4) 3 (4) 1 (4) Combined therapy 29 (3) 27 (3) 2 (2) 1 (3) Prior exposure to nephrotoxic chemotherapy 309 (30) 276 (30) 33 (40) 1…”
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805131 · Cited by 1,411
Competing Risk Regression Models for Epidemiologic Data
Lau, B., Cole, S. R., & Gange, S. J. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp107 · Cited by 1,403
Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
Levey, A. S., & Stevens, L. A. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.02.337 · Cited by 1,005
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., Le, D. T., Lipson, E. J., Glezerman, I. G., Wolchok, J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.008 · Cited by 650
Self-citationFaje, A. T., Lawrence, D., Flaherty, K., Freedman, C., Fadden, R., Rubin, K., Cohen, J., & Sullivan, R. J. (2018) · Cancer · doi:10.1002/cncr.31629 · Cited by 486
Self-citationAnti-CTLA4 Antibody–Induced Lupus Nephritis
Fadel, F., Karoui, K. E., & Knebelmann, B. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904283 · Cited by 300
Mamlouk, O., Selamet, U., Machado, S., Abdelrahim, M., Glass, W. F., Tchakarov, A., Gaber, L., Lahoti, A., Workeneh, B., Chen, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0478-8 · Cited by 296
Shirali, A. C., Perazella, M. A., & Gettinger, S. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.02.057 · Cited by 284
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
Kliger, A. S., Foley, R. N., Goldfarb, D. S., Goldstein, S. L., Johansen, K., Singh, A., & Szczech, L. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.06.008 · Cited by 270
Renal toxicities associated with pembrolizumab
Izzedine, H., Mathian, A., Champiat, S., Picard, C., Mateus, C., Routier, É., Varga, A., Malka, D., Leary, A. F., Michels, J., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy100 · Cited by 133
Cardiorenal complications of immune checkpoint inhibitors
Sury, K., Perazella, M. A., & Shirali, A. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0035-1 · Cited by 108
Renal complications of immune checkpoint blockade
Murakami, N., Motwani, S. S., & Riella, L. V. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.004 · Cited by 104
Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition
van den Brom, R. R. H., Abdulahad, W. H., Rutgers, A., Kroesen, B., Roozendaal, C., de Groot, D. J. A., Schröder, C. P., Hospers, G. A. P., & Brouwer, E. (2016) · Lara D. Veeken · doi:10.1093/rheumatology/kew063 · Cited by 73
Gibson, A., Faulkner, L., Lichtenfels, M., Ogese, M. O., Al-Attar, Z. I., Alfirevic, A., Esser, P. R., Martin, S. F., Pirmohamed, M., Park, B. K., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1602029 · Cited by 50
Cited by
Haanen, J., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C., Lyon, A. R., Wick, W., Kostine, M., Peters, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.001 · Cited by 1,311
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Self-citationThe adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Drug-Induced Acute Kidney Injury
Perazella, M. A., & Rosner, M. H. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11290821 · Cited by 357
Chennamadhavuni, A., Abushahin, L., Jin, N., Presley, C. J., & Manne, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.779691 · Cited by 344
Metadata
- Authors
- Seethapathy, H., Zhao, S., Chute, D. F., Zubiri, L., Oppong, Y., Strohbehn, I., Cortazar, F. B., Leaf, D. E., Mooradian, M. J., Villani, A.-C., Sullivan, R. J., Reynolds, K., & Sise, M. E.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2019-10-31
- Volume
- 14
- Issue
- 12
- Pages
- 1692-1700
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- OpenAlex
- W2984413960
- Cited by
- 304
- References
- 32
- FWCI
- 23.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.